Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result Database

Abstract

ObjectiveRadiation therapy (RT) for esophageal cancer often results in unintended radiation doses delivered to the heart owing to anatomic proximity. Using the Surveillance, Epidemiology, and End Results (SEER) database, we examined late cardiac death in survivors of esophageal cancer that had or had not received RT.Methods5,630 patients were identified that were diagnosed with esophageal squamous cell carcinoma (SCC) or adenocarcinoma (AC) from 1973–2012, who were followed for at least 5 years after therapy. Examined risk factors for cardiac death included age (≤55/56-65/66-75/>75), gender, race (white/non-white), stage (local/regional/distant), histology (SCC/AC), esophageal location (<18cm/18-24cm/25-32cm/33-40cm from incisors), diagnosis year (1973-1992/1993-2002/2003-2012), and receipt of surgery and/or RT. Time to cardiac death was evaluated using the Kaplan-Meier method. A Cox model was used to evaluate risk factors for cardiac death in propensity score matched data.ResultsPatients who received RT were younger, diagnosed more recently, had more advanced disease, SCC histology, and no surgery. The RT group had higher risk of cardiac death than the no-RT group (log-rank p<0.0001). The median time to cardiac death in the RT group was 289 months (95% CI, 255–367) and was not reached in the no-RT group. The probability of cardiac death increased with age and decreased with diagnosis year, and this trend was more pronounced in the RT group. Multivariate analysis found RT to be associated with higher probability of cardiac death (OR 1.23, 95% CI 1.03–1.47, HR 1.961, 95% CI 1.466–2.624). Lower esophageal subsite (33–40 cm) was also associated with a higher risk of cardiac death. Other variables were not associated with cardiac death.ConclusionsRecognizing the limitations of a SEER analysis including lack of comorbidity accountability, these data should prompt more definitive study as to whether a possible associative effect of RT on cardiac death could potentially be a causative effect.

Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base

“…This is consistent with a retrospective single-institution report of HD therapy being associated with more acute adverse effects and potentially suboptimal surgical conditions (23). Nevertheless, in light of studies demonstrating that advanced RT techniques may decrease adverse and postoperative events, further work must assess whether a decrease in dose has additive effects as well (24)(25)(26)(27)(28).…”

Advances in Radiotherapy Management of Esophageal Cancer

“…Since radiotherapy is an important component in the management of EC, the delivery of radiotherapy is an important consideration given the critical organs of the heart and lung that surround tumors in the mid to distal esophagus [20]. Radiotherapy in this area delivers a significant dose to the surrounding organs, and therefore advanced techniques to reduce the dose exposure of these organs will mitigate the toxicities and improve outcomes for patients.…”

Dosimetric comparison of distal esophageal carcinoma plans for patients treated with small‐spot intensity‐modulated proton versus volumetric‐modulated arc therapies

“…The long‐term results of Radiation Therapy Oncology Group (RTOG) clinical trial 85‐01 confirmed that chemoradiation increased overall survival for patients with esophageal carcinoma compared with radiotherapy (RT) alone . Due to proximity to surrounding organs at risk (OAR) such as heart, spinal cord, lungs, kidney, liver, and the remaining stomach, the RT planning for distal esophagus carcinoma poses special challenges . Sufficient radiation doses must be applied to the tumor and lymph node areas, while protecting nearby critical normal structures.…”